Skip to content

Arrowhead Research ARWR Net gains (losses) on investments

Net gains (losses) on investments at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$22.58M+1,144%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$18.28M-17.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$25.3M+183%
Amgen logo
AmgenAMGN
-$143M-111%
Roivant Sciences logo
Roivant SciencesROIV
$21.59M+201%
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's net gains (losses) on investments?
Arrowhead Research (ARWR) reported net gains (losses) on investments of -$6.72M in Q1 2026.
What is the long-term trend for Arrowhead Research's net gains (losses) on investments?
Over 2 years (2021 to 2023), Arrowhead Research's net gains (losses) on investments has grown at a -100.0% compound annual growth rate (CAGR), from $1.71M to $0.